Janux Therapeutics, Inc. (JANX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US47103J1051
Janux Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 10.00 m USD |
| Operating income | -157.67 m USD |
| EBIT | -113.63 m USD |
| Net income | -113.63 m USD |
| Diluted EPS – continuing operations | -1.83 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
More stocks
- Burelle SA (BUR.PA)
- Hengbao Co Ltd (002104.SZ)
- Ramsay Generale de Sante SA (GDS.PA)
- Odfjell SE (ODF.OL)
- Seneca Foods Corp (SENEA)
- Reformation Inc. (REF)
- Intuitive Machines, Inc. (LUNR)
- Ficont Industry (Beijing) Co. Ltd. (605305.SS)
- ZX PACKING ORD A (SHH) EQSW Exp: (603091.SS)
- Corticeira Amorim SGPS SA (COR.LS)
- INFRACORE SA (INFRAC.SW)
- Ituran Location and Control Ltd (ITRN)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.